Use of polypharmacy and self-reported mood in outpatients with bipolar disorder

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 4, 2005, Pages 251-256

  Adli, Mazda ^a   Whybrow, Peter C ^b   Grof, Paul ^c   Rasgon, Natalie ^b,e   Gyulai, Laszlo ^d   Baethge, Christopher ^a   Glenn, Tasha ^f   Bauer, Michael ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROYAL OTTAWA HOSPITAL   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ChronoRecord Association Inc   (United States)

Author keywords

Bipolar disorder; Combination therapy; Polypharmacy; Self reported mood

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; THYROID HORMONE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG DOSE REGIMEN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT INFORMATION; POLYPHARMACY; PRIORITY JOURNAL; SAMPLE SIZE; SELF REPORT; STATISTICAL ANALYSIS;

EID: 27844586848     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510029200     Document Type: Article

References (51)

1. Hsu DJ, Ghaemi SN, Thase ME, et al. Pharmacological treatment of bipolar disorder: Psychotropic medication use in the first 500 patients in the Systemic Treatment Enchancement Program for Bipolar Disorders. Bipolar Disord 2003;5(Suppl 1):26.
2. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;159:1005-10.
3. Szarez BL, Goethe JW, Farheem US, et al. Prescribing practices in bipolar disorder. Program and abstracts of the APA 155th Annual Meeting, May 18-23, Philadelphia, PA. Scientific Session 14; 2002.
4. Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000;2:120-30.
5. Ghaemi N, editor. Polypharmacy in psychiatry. New York: Marcel Dekker Inc; 2002.
6. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42.
7. Gitlin MJ, Swendsen J, Heller TL, et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-40.
8. Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002;359:241-7.
9. Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the 'top 10' physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:5-14.
10. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness - 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:213-9.
11. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-104.
12. Shapiro DR, Quitkin FM, Fleiss JL. Response to maintenance therapy in bipolar illness. Effect of index episode. Arch Gen Psychiatry 1989;46:401-5.
13. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991;48:62-8.
14. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48:915-21.
15. Frankenburg FR, Tohen M, Cohen BM, et al. Long-term response to carbamazepine: A retrospective study. J Clin Psychopharmacol 1988;8:130-2.
16. Preskorn SH. Polypharmacy: When is it rational? J Pract Psychiatry Behav Health 1995;1:92-8.
17. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. J Am Med Assoc 1990;264:2511-8.
18. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 2002;68:1-23.
19. Merikangas KR, Angst J, Eaton W, et al. Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. Br J Psychiatry (Suppl) 1996;30:58-67.
20. Ucok A, Karaveli D, Kundakci T, et al. Comorbidity of personality disorders with bipolar mood disorders. Compr Psychiatry 1998;39:72-4.
21. Yatham LN, Kusumakar V, Calabrese JR, et al. Third generation anticonvulsants in bipolar disorder: A review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002;63:275-83.
22. Olfson M, Marcus SC, Pincus HA. Trends in office-based psychiatric practice. Am J Psychiatry 1999;156:451-7.
23. Woolston JL. Combined pharmacotherapy: Pitfalls of treatment. J Am Acad Child Adolesc Psychiatry 1999;38:1455-7.
24. Bauer M, Grof P, Gyulai L, et al. Using Technology to Improve Longitudinal Studies: Self-Reporting in Bipolar Disorder. Bipolar Disord 2004;6:67-74.
25. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;(Suppl 20):22-33.
26. Bauer MS, Crits-Christoph P, Ball WA, et al. Independent assessment of manic and depressive symptoms by self-rating. Scale characteristics and implications for the study of mania. Arch Gen Psychiatry 1991;48:807-12.
27. Bauer M, Neuhaus K, Sasse J, et al. Validation of ChronoRecord Self-Reporting Software by inpatients with mania. American Psychiatric Association 2005 Annual Meeting New Research Poster Session. 2005. Atlanta, GA.
28. Whybrow PC, Grof P, Gyulai L, et al. The electronic assessment of the longitudinal course of bipolar disorder: The ChronoRecord Software. Pharmacopsychiatry 2003;36(Suppl 3):244-9.
29. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680-90.
30. Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63:120-5.
31. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
32. Goodwin FK, Jamison KR. Manic depressive illness. New York: Oxford University Press Inc; 1990.
33. Goldberg JF, Garno JL, Leon AC, et al. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999;60:733-40.
34. Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106-11.
35. Post RM, Ketter TA, Pazzaglia PJ, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Research 1996;(Suppl 11):153-80.
36. Post RM, Frye MA, Leverich GS, et al. The role of complex combination therapy in the treatment of refractory bipolar illness. CNS Spectrums 1998;3:66-86.
37. Geddes J, Goodwin G. Bipolar disorder: Clinical uncertainty, evidence-based edicine and large-scale randomised trials. Br J Psychiatry 2001;(Suppl 41):S191-4.
38. Freeman MP, Stoll AL. Mood stabilizer combinations: A review of safety and efficacy. Am J Psychiatry 1998;155:12-21.
39. Solomon DA, Keitner GI, Ryan CE, et al. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: A review. J Clin Psychopharmacol 1998;18:38-49.
40. Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000;48:573-81.
41. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45.
42. Duffy A, Grof P. Psychiatric diagnoses in the context of genetic studies of bipolar disorder. Bipolar Disord 2001;3:270-5.
43. Passmore MJ, Garnham J, Duffy A, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003;5:110-4.
44. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000;42(Suppl 1):2-10.
45. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex versus lithium and placebo in the treatment of mania. The Depakote Mania Study Group. J Am Med Assoc 1994;271:918-4.
46. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-9.
47. Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry 2003;64(Suppl 5):53-61.
48. Ketter TA, Wang PW. Predictors of treatment response in bipolar disorders: Evidence from clinical and brain imaging studies. J Clin Psychiatry 2002;63(Suppl 3):21-5.
49. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2:249-55.
50. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-71.
51. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607-14.